Livingstone Health looks beyond Sinovac boost; to broaden range of services
The multi-disciplinary healthcare group does not want to specialise too narrowly.
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
BEING appointed to lead Sinovac procurement for Singapore's private healthcare institutions might be seen as something of a coup for Livingstone Health Holdings. But chief executive officer Wilson Tay does not wish to overstate the significance of that Covid-19 vaccine's contribution to the healthcare group's prospects.
Seeing it more as "national service", he considers it a non-core part of Livingstone's business - although the healthcare group's "core business" is itself very diverse.
In the half-year ended Sep 30, revenue from the company's family medicine segment rose S$2.2 million "mainly due to the revenue generated from sale and administration of (the) Sinovac vaccine in September 2021". Subsidiary Livingstone Health International had been appointed to do so by the Health Ministry that month.
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Copyright SPH Media. All rights reserved.
